about
Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenesBenzocaine complexation with p-sulfonic acid calix[n]arene: experimental ((1) H-NMR) and theoretical approaches.Synthetic approaches to mixed ligand chelators on t-butylphenol-formaldehyde oligomer (PFO) platforms.Applications of nano-baskets in drug development: high solubility and low toxicity.Biological applications of functionalized calixarenes.Xanthenones: calixarenes-catalyzed syntheses, anticancer activity and QSAR studies.Design of Organic Macrocycle-Modified Iron Oxide Nanoparticles for Drug Delivery.Functionalized calix[4]arenes as potential therapeutic agents.Cellular uptake of a fluorescent vanadyl sulfonylcalix[4]arene.Synthesis, biological evaluation and molecular docking of calix[4]arene-based β-diketo derivatives as HIV-1 integrase inhibitors.Virus-sized DNA nanoparticles for gene delivery based on micelles of cationic calixarenes.Chemistry and engineering of cyclodextrins for molecular imaging.Patent Highlights June-July 2017.Calix[4]arene methylenebisphosphonic acids as inhibitors of fibrin polymerization.Solvatomorphs of 25,26,27,28-tetrahydroxycalix[4]arene and 5,11,17,23-tetramino-25,26,27,28-tetrabutoxycalix[4]arene: quenching photoluminescence through switching the guestComplexes of fluconazole with sodium p-sulfonatocalix[n]arenes: characterization, solubility and antifungal activityInclusion complexes of Schiff bases as phytogrowth inhibitorsOrganocatalysis in the three-component Povarov reaction and investigation by mass spectrometryNMR studies of inclusion complexation of the pyrrolizidine alkaloid retronecine and p-sulfonic acid calix[6]arene
P2860
Q30615373-77F4953E-1A3E-4F21-84C0-60FBA083ECFDQ30704240-FA806181-0F4C-4018-B64E-214A0E5EF117Q36443862-87859091-AC41-453A-A495-E9BFBCC07F98Q37987604-E95374AD-B542-4C13-ADDB-1068EBCE7C06Q38049083-5B9B0C76-17F7-4E5F-B726-C78F6692E581Q38913704-B2DFFC57-8E20-4F72-B798-44FBD02FF93EQ39121482-17656FFE-689E-49DD-8B9A-399442F6F821Q39138272-59EB58AB-F06E-4210-BDA6-11A58FA50670Q39429961-5AC3A4E9-23CF-4F34-82F0-1E6B8F77B439Q42164732-E2B5A0C6-1B62-4076-ACE4-9C41A435FC35Q45367245-00680A5B-6CFC-47BB-8F77-97304A00373EQ47568662-70919519-2978-467E-B0CF-A3D6C330DA30Q50075584-BF383E7A-E9E8-40E9-9556-DC4E660CF376Q53891210-E96EB3DD-A9CD-4091-9AFC-66C2258824D1Q58822279-2D676798-D173-4A1B-9294-1CFCD069F522Q58822307-2A0C2070-62BE-463C-A917-56DDE2781DE3Q58822336-6C7F99FE-CEF1-43F5-9893-2DE2A4999899Q58822339-2CF2CE47-2816-4C1C-9E52-6B7562AEEDAAQ58822354-745E6210-DA26-4C91-8FE1-D430B87ADDAE
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Calixarenes as new platforms for drug design.
@en
Calixarenes as new platforms for drug design.
@nl
type
label
Calixarenes as new platforms for drug design.
@en
Calixarenes as new platforms for drug design.
@nl
prefLabel
Calixarenes as new platforms for drug design.
@en
Calixarenes as new platforms for drug design.
@nl
P2093
P1476
Calixarenes as new platforms for drug design.
@en
P2093
Adão Aparecido Sabino
Angelo de Fátima
Sergio Antonio Fernandes
P304
P356
10.2174/157016309788488302
P577
2009-06-01T00:00:00Z